LifeMD, Inc. (LFMD) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Medical - Pharmaceuticals
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low93.1·High93.1
P/FCF
↓
33.61
↓-97% vs avg
5yr avg: 1096.93
30Y Low23.6·High91.9
P/B Ratio
↑
8.75
↓-57% vs avg
5yr avg: 20.40
30Y Low4.0·High50.5
ROE
↑
-74.4%
↓+90% vs avg
5yr avg: -781.3%
30Y Low-492%·High-74%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.0·High1.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LFMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
LifeMD, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 33.6x P/FCF, 97% below the 5-year average of 1096.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $215M | $154M | $204M | $281M | $60M | $105M | $93M | $6M | $6M | $15M | $9M |
| Enterprise Value | $185M | $123M | $194M | $267M | $60M | $65M | $85M | $6M | $6M | $15M | $9M |
| P/E Ratio → | -19.52 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.11 | 0.79 | 0.96 | 1.84 | 0.50 | 1.13 | 2.50 | 0.48 | 0.76 | 2.96 | 1.75 |
| P/B Ratio | 8.75 | 6.65 | — | 50.50 | — | 4.05 | — | — | 7.73 | 24.01 | — |
| P/FCF | 33.61 | 24.01 | 34.12 | 3232.66 | — | — | — | 23.62 | — | — | — |
| P/OCF | 26.01 | 18.59 | 11.64 | 31.87 | — | — | — | 23.62 | — | — | — |
P/E links to full P/E history page with 30-year chart
LFMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.64 | 0.91 | 1.75 | 0.51 | 0.70 | 2.28 | 0.46 | 0.77 | 2.96 | 1.75 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 93.14 | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 19.26 | 32.46 | 3069.18 | — | — | — | 22.58 | — | — | — |
LFMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
LifeMD, Inc. earns an operating margin of -4.0%. Operating margins have expanded from -9.5% to -4.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -74.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.8% | 79.8% | 88.7% | 87.6% | 84.3% | 80.6% | 76.2% | 79.7% | 76.3% | 70.6% | 62.9% |
| Operating Margin | -4.0% | -4.0% | -7.6% | -9.5% | -36.5% | -58.5% | -155.0% | -23.2% | -24.7% | -21.1% | -22.4% |
| Net Profit Margin | -3.7% | -3.7% | -8.9% | -13.5% | -38.3% | -65.6% | -157.3% | -25.2% | -14.9% | -23.9% | -21.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -74.4% | -2483.1% | -370.0% | -491.9% | -487.2% | — | — | -172.0% | -923.7% | — |
| ROA | -9.9% | -9.9% | -28.8% | -49.0% | -120.5% | -192.3% | -696.1% | -103.5% | -64.0% | -117.4% | -178.9% |
| ROIC | — | — | — | — | — | — | — | — | -200.8% | -514.9% | — |
| ROCE | -37.4% | -37.4% | -89.9% | -161.1% | -406.3% | -408.8% | — | -646.1% | -200.9% | -817.7% | — |
LFMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $37M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | — | 3.40 | — | 0.07 | — | — | 0.30 | 0.27 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 1.04 | — |
| Net Debt / Equity | — | -1.32 | — | -2.55 | — | -1.53 | — | — | 0.08 | 0.04 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.16 | — |
| Debt / FCF | — | -4.75 | -1.66 | -163.48 | — | — | — | -1.04 | — | — | — |
| Interest Coverage | -5.64 | -5.64 | -7.40 | -5.58 | -31.10 | -17.98 | -34.67 | -3.80 | -5.80 | -12.72 | -24.16 |
Net cash position: cash ($37M) exceeds total debt ($6M)
LFMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.25x means LifeMD, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | 1.25 | 0.81 | 1.22 | 0.36 | 1.97 | 0.89 | 0.69 | 1.35 | 1.97 | 0.69 |
| Quick Ratio | 1.18 | 1.18 | 0.76 | 1.15 | 0.24 | 1.90 | 0.80 | 0.45 | 0.49 | 0.87 | 0.55 |
| Cash Ratio | 0.88 | 0.88 | 0.58 | 0.95 | 0.13 | 1.81 | 0.66 | 0.28 | 0.15 | 0.22 | 0.16 |
| Asset Turnover | — | 2.76 | 2.93 | 2.61 | 4.64 | 1.86 | 2.78 | 3.62 | 3.18 | 4.00 | 6.63 |
| Inventory Turnover | 14.17 | 14.17 | 8.60 | 6.85 | 5.04 | 11.13 | 7.01 | 2.66 | 1.93 | 2.10 | 12.14 |
| Days Sales Outstanding | — | 17.50 | 14.12 | 12.63 | 8.69 | 3.85 | 9.77 | 2.85 | 4.34 | 9.26 | 31.14 |
LFMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
LifeMD, Inc. returns 1.5% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.5% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 3.0% | 4.2% | 2.9% | 0.0% | — | — | — | 4.2% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.9% |
| Total Shareholder Yield | 1.5% | 2.0% | 1.5% | 1.1% | 5.2% | 0.8% | 1.4% | 0.0% | 0.0% | 0.5% | 0.9% |
| Shares Outstanding | — | $45M | $41M | $34M | $31M | $27M | $14M | $10M | $9M | $9M | $7M |
Peer Comparison
Compare LFMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LFMDYou | $215M | -19.5 | — | 33.6 | 79.8% | -4.0% | -74.4% | — | — |
 HIMS | $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 DOCS | $5B | 23.5 | 21.1 | 19.6 | 90.2% | 39.9% | 22.5% | 20.0% | 0.1 |
 OPRX | $124M | 24.6 | 6.5 | 6.6 | 67.3% | 10.7% | 4.2% | 7.1% | 0.3 |
 TDOC | $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 AMWL | $129M | -1.3 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 TALK | $868M | 129.5 | 137.8 | — | 43.0% | 1.4% | 6.6% | 3.9% | — |
 GDRX | $973M | 33.3 | 4.0 | 5.9 | 82.1% | 13.4% | 4.5% | 13.0% | 0.3 |
 PHVS | $2B | -10.2 | — | — | — | — | -41.2% | — | — |
 CVS | $111B | 62.8 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See LFMD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LFMD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LFMD vs HIMS
Side-by-side business, growth, and profitability comparison vs Hims & Hers Health, Inc..
Start ComparisonLFMD — Frequently Asked Questions
Quick answers to the most common questions about buying LFMD stock.
What is LifeMD, Inc.'s P/E ratio?
LifeMD, Inc.'s current P/E ratio is -19.5x. This places it at the 50th percentile of its historical range.
What is LifeMD, Inc.'s ROE?
LifeMD, Inc.'s return on equity (ROE) is -74.4%. The historical average is -298.4%.
Is LFMD stock overvalued?
Based on historical data, LifeMD, Inc. is trading at a P/E of -19.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is LifeMD, Inc.'s dividend yield?
LifeMD, Inc.'s current dividend yield is 1.53%.
What are LifeMD, Inc.'s profit margins?
LifeMD, Inc. has 79.8% gross margin and -4.0% operating margin.